Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Rahul Bisht, Arusha Desai, Esteban Marcelo Mogrovejo Carrión et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of mepolizumab in patients with eosinophilic chronic obstructive pulmonary disease (COPD). Analyzing data from four randomized controlled trials involving 1953 patients, the study found that mepolizumab significantly prolonged the time to first moderate or severe exacerbation (HR = 0.80) and reduced the rate of exacerbations (rate ratio 0.80).
Key findings
- Mepolizumab prolonged the time to first moderate or severe exacerbation (HR = 0.80; 95% CI 0.69-0.92; P = 0.016).
- The rate of moderate-to-severe exacerbations was reduced (rate ratio 0.80; 95% CI 0.78-0.83; P < 0.001).
- The risk of serious adverse events or death was significantly lower in the mepolizumab group (RR = 0.83; 95% CI 0.72-0.96; P = 0.031).
- The risk of adverse events was similar between mepolizumab and placebo groups (RR = 1.00; 95% CI 0.95-1.06; P = 0.962).
Why it matters
The findings suggest that mepolizumab may offer a targeted treatment option for eosinophilic COPD, potentially reducing exacerbations without increasing safety concerns associated with other therapies, which is crucial for improving patient outcomes.